Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $922,400.00 in Stock

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) General Counsel Andrew Fisher sold 80,000 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $11.53, for a total transaction of $922,400.00. Following the transaction, the general counsel now owns 359,999 shares of the company's stock, valued at $4,150,788.47. This trade represents a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Andrew Fisher also recently made the following trade(s):

• On Tuesday, April 29th, Andrew Fisher sold 26,072 shares of Verona Pharma PLC American Depositary Share stock. The shares were sold at an average price of $8.98, for a total transaction of $234,126.56.

Verona Pharma PLC American Depositary Share Trading Down 2.2%

Shares of Verona Pharma PLC American Depositary Share stock traded down $2.01 during trading hours on Wednesday, reaching $90.92. 1,008,504 shares of the company's stock were exchanged, compared to its average volume of 1,456,383. Verona Pharma PLC American Depositary Share has a 52-week low of $14.14 and a 52-week high of $94.45. The company has a fifty day moving average of $72.55 and a 200-day moving average of $61.14. The company has a current ratio of 8.86, a quick ratio of 8.73 and a debt-to-equity ratio of 1.07. The firm has a market capitalization of $7.37 billion, a price-to-earnings ratio of -45.46 and a beta of 0.21.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.49. The business had revenue of $98.65 million for the quarter, compared to analysts' expectations of $41.47 million. Sell-side analysts forecast that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of VRNA. RTW Investments LP acquired a new stake in shares of Verona Pharma PLC American Depositary Share in the fourth quarter worth approximately $84,568,000. Adage Capital Partners GP L.L.C. increased its position in Verona Pharma PLC American Depositary Share by 381.9% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,631,000 shares of the company's stock worth $103,552,000 after purchasing an additional 1,292,575 shares during the last quarter. Wellington Management Group LLP raised its stake in Verona Pharma PLC American Depositary Share by 61.0% during the fourth quarter. Wellington Management Group LLP now owns 3,025,241 shares of the company's stock worth $140,492,000 after purchasing an additional 1,146,609 shares during the period. Lord Abbett & CO. LLC purchased a new position in Verona Pharma PLC American Depositary Share during the first quarter worth approximately $58,716,000. Finally, Darwin Global Management Ltd. acquired a new position in shares of Verona Pharma PLC American Depositary Share in the 4th quarter valued at $37,637,000. Institutional investors and hedge funds own 85.88% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on VRNA shares. Wells Fargo & Company increased their price target on shares of Verona Pharma PLC American Depositary Share from $93.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, April 30th. HC Wainwright increased their target price on Verona Pharma PLC American Depositary Share from $85.00 to $90.00 and gave the company a "buy" rating in a report on Monday, June 2nd. Cantor Fitzgerald raised their price target on Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the stock an "overweight" rating in a research report on Wednesday, June 11th. Roth Capital reissued a "buy" rating and issued a $116.00 price target (up from $92.00) on shares of Verona Pharma PLC American Depositary Share in a report on Wednesday. Finally, TD Cowen began coverage on Verona Pharma PLC American Depositary Share in a research note on Monday, April 28th. They set a "buy" rating and a $100.00 price objective on the stock. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $91.11.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.